Yoshihiro Miyahara

Yoshihiro Miyahara, M.D., Ph.D.

Associate Professor

Contact information

Email: miyahr-y@clin.medic.mie-u.ac.jp

Profiles and Research Field

After graduation from Mie University School of Medicine, he entered the Second Department of Internal Medicine, and moved to Baylor College of Medicine (Houston, Texas) and then Toledo University (Toledo, Ohio). After returning to Japan, he started his work as a lecture at Department of Cancer Vaccine, Mie University Graduate School of Medicine. From May 2016, he worked as associate professor at Department of Immuno-Gene Therapy. From March 2018, he has been working as associate professor at Department of Personalized Cancer Immunotherapy. His current research interests are analysis of immune responses and development of effective personalized cancer immunotherapy.

Academic societies

Japan Cancer Association, Japan Association of Cancer Immunology, Japan Society for Immunology, European Society of Gene and Cell Therapy

Research title

Recent Publications

  1. Oda H, Ishihara M, Miyahara Y, Nakamura J, Kozuka Y, Iwasa M, Tsunoda A, Yamashita Y, Saito K, Mizuno T, Shiku H, Katayama N. First Case of Cytokine Release Syndrome after Nivolumab for Gastric Cancer. Case Rep Oncol. 2019 Feb 8;12(1):147-156.

     

  2. Muraoka D, Seo N, Hayashi T, Tahara Y, Fujii K, Tawara I, Miyahara Y, Okamori K, Yagita H, Imoto S, Yamaguchi R, Komura M, Miyano S, Goto M, Sawada S, Asai A, Ikeda H, Akiyoshi K, Harada N, and Shiku H. Antigen Delivery Targeting Tumor-Associated Macrophages Overcomes Tumor Immune Resistance. J Clin Invest. 2019 Mar 1;129(3):1278-1294.

     

  3. Akahori Y, Wang L, Yoneyama M, Seo N, Okumura S, Miyahara Y, Amaishi Y, Okamoto S, Mineno J, Ikeda H, Maki T, Fujiwara H, Akatsuka Y, Kato T, Shiku H. Antitumor activity of CAR-T cells targeting the intracellular oncoprotein WT1 can be enhanced by vaccination. Blood. 2018 Sep 13;132(11):1134-1145.

     

  4. Tono Y, Ishihara M, Miyahara Y, Tamaru S, Oda H, Yamashita Y, Tawara I, Ikeda H, Shiku H, Mizuno T, Katayama N. Pertuzumab, trastuzumab and eribulin mesylate therapy for previously treated advanced HER2-positive breast cancer: a feasibility study with analysis of biomarkers. Oncotarget. 2018 Feb 16;9(19):14909-14921.

     

  5. Wada M, Tsuchikawa T, Kyogoku N, Abiko T, Miyauchi K, Takeuchi S, Kuwatani T, Shichinohe T, Miyahara Y, Kageyama S, Ikeda H, Shiku H, Hirano S. Clinical Implications of CD4+CD25+Foxp3+Regulatory T Cell Frequencies After CHP-MAGE-A4 Cancer Vaccination. Anticancer Res. 2018 Mar;38(3):1435-1444.

     

  6. Abiko T, Tsuchikawa T, Miyauchi K, Wada M, Kyogoku N, Shichinohe T, Miyahara Y, Kageyama S, Ikeda H, Shiku H, Hirano S. Serum immunoglobulin E response as a marker for unfavorable prognosis following cholesteryl pullulan-MAGE A4 vaccination. Oncol Lett. 2018 Mar;15(3):3703-3711.

     

  7. Tawara I, Kageyama S, Miyahara Y, Fujiwara H, Nishida T, Akatsuka Y, Ikeda H, Tanimoto K, Terakura S, Murata M, Inaguma Y, Masuya M, Inoue N, Kidokoro T, Okamoto S, Tomura D, Chono H, Nukaya I, Mineno J, Naoe T, Emi N, Yasukawa M, Katayama N, Shiku H. Safety and persistence of WT1-specific T-cell receptor gene-transduced lymphocytes in patients with AML and MDS. Blood. 2017 Nov 2;130(18):1985-1994.

     

  8. Fujii K, Miyahara Y, Harada N, Muraoka D, Komura M, Yamaguchi R, Yagita H, Nakamura J, Sugino S, Okumura S, Imoto S, Miyano S, Shiku H. Identification of an immunogenic neo-epitope encoded by mouse sarcoma using CXCR3 ligand mRNAs as sensors. Oncoimmunology. 2017 Mar 20;6(5):e1306617.

     

  9. Kyogoku N, Ikeda H, Tsuchikawa T, Abiko T, Fujiwara A, Maki T, Yamamura Y, Ichinokawa M, Tanaka K, Imai N, Miyahara Y, Kageyama S, Shiku H, Hirano S. Time-dependent transition of the immunoglobulin G subclass and immunoglobulin E response in cancer patients vaccinated with cholesteryl pullulan-melanoma antigen gene-A4 nanogel. Oncol Lett. 12(6):4493-4504. 2016

     

  10. Miyauchi K, Tsuchikawa T, Wada M, Abiko T, Kyogoku N, Shichinohe T, Miyahara Y, Kageyama S, Ikeda H, Shiku H, Hirano S. Clinical relevance of antigen spreading pattern induced by CHP-MAGE-A4 cancer vaccination. Immunotherapy. 8(5):527-540, 2016.

     

  11. Guidance Development Review Committee; Working Group for Clinical Studies of Cancer Immunotherapy; Working Group for Effector Cell Therapy; Working Group for CMC/Non-clinical Studies; Working Group for Cancer Vaccines and Adjuvants; Working Group for Anti-immune Checkpoint Therapy and Comprehensive Cancer Immunotherapy; Biostatistics Subcommittee. 2015 Guidance on cancer immunotherapy development in early-phase clinical studies. Cancer Sci. 106(12):1761-1771, 2015.

     

  12. Kageyama S, Ikeda H, Miyahara Y, Imai N, Ishihara M, Saito K, Sugino S, Ueda S, Ishikawa T, Kokura S, Naota H, Ohishi K, Shiraishi T, Inoue N, Tanabe M, Kidokoro T, Yoshioka H, Tomura D, Nukaya I, Mineno J, Takesako K, Katayama N, Shiku H. Adoptive Transfer of MAGE-A4 T-cell Receptor Gene-Transduced Lymphocytes in Patients with Recurrent Esophageal Cancer. Clin Cancer Res. 21(10):2268-2277, 2015.

     

  13. Schroder PM, Khattar M, Baum CE, Miyahara Y, Chen W, Vyas R, Muralidharan S, Mierzejewska B, Stepkowski SM. PD-1-dependent restoration of self-tolerance in the NOD mouse model of diabetes after transient anti-TCRβ mAb therapy. Diabetologia.58(6):1309-18. 2015.

     

  14. Khattar M, Miyahara Y, Schroder PM, Xie A, Chen W, Stepkowski SM. Interleukin-21 Is a Critical Regulator of CD4 and CD8 T Cell Survival during Priming under Interleukin-2 Deprivation Conditions. PLoSOne.9;9(1):e85882.2014

     

  15. Kageyama S, Wada H, Muro K, Niwa Y, Ueda S, Miyata H, Takiguchi S, Sugino SH, Miyahara Y, Ikeda H, Imai N, Sato E, Yamada T, Osako M, Ohnishi M, Harada N, Hishida T, Doki Y, Shiku H. Dose-dependent effects of NY-ESO-1 protein vaccine complexed with cholesteryl pullulan (CHP-NY-ESO-1) on immune responses and survival benefits of esophageal cancer patients. J Transl Med. 11:246, 2013.

     

  16. Miyahara Y, Guo Z, Wang G, He X, Chen W, Stepkowski SM. A dynamic dual role of IL-2 signaling in the two-step differentiation process of adaptive regulatory T cells. J Immunol. 1;190(7):3153-62.2013.

     

  17. Miyahara Y, Khattar M, Schroder PM, Mierzejewska B, Deng R, Han R, Hancock WW, Chen W, Stepkowski SM.Anti-TCRβ mAb induces long-term allograft survival by reducing antigen-reactive T cells and sparing regulatory T cells. Am J Transplant. 12(6):1409-18.2012.

     

  18. Iwamura K, Kato T, Miyahara Y, Naota H, Mineno J, Ikeda H, Shiku H. siRNA-mediated silencing of PD-1 ligands enhances tumor-specific human T-cell effector functions. Gene Ther. 19(10):959-66.2012.

     

  19. Tsuda K, Yamanaka K, Linan W, Miyahara Y, Shiku H, Gabazza EC, Mizutani H. Intratumoral injection of Propionibacterium acnes suppresses malignant melanoma by enhancing Th1 immune responses. PLoS One. 6(12):e29020.2011.

     

  20. Wang G, Khattar M, Guo Z, Miyahara Y, Linkes SP, Sun Z, He X, Stepkowski SM, Chen W. IL-2-deprivation and TGF-beta are two non-redundant suppressor
    mechanisms of CD4+CD25+ regulatory T cell which jointly restrain CD4+CD25- cell activation. Immunol Lett. 132:61-68, 2010.

     

  21. Miyahara Y, Wang G, Guo Z, Khattar M, Stepkowski SM, Chen W. “Default”
    Generation of Neonatal Regulatory T Cells. J Immunol. 185:71-78, 2010.

     

  22. Guo Z, Wang G, Miyahara Y, Khattar M, Linkes SP, Wang C, Xia J, Pan Y, Chen W, He X, Stepkowski SM. IL-7, but not thymic stromal lymphopoietin (TSLP), during priming enhances the generation of memory CD4(+) T cells. Immunol Lett. 128:116-123, 2010.